Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients
Abstract Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore,...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Oncology 2024-01, Vol.17 (1), p.208-216 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 1 |
| container_start_page | 208 |
| container_title | Case Reports in Oncology |
| container_volume | 17 |
| creator | Sato, Shoko Imada, Sae Hayami, Ryosuke Arai, Kazumori Kosugi, Rieko Tsuneizumi, Michiko Matsunuma, Ryoichi |
| description | Abstract
Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore, the considerations for adjuvant endocrine therapy in this population are highly intricate and warrant thorough discussion. Case Presentation: We describe the case of a 44-year-old FtM transgender diagnosed with breast cancer 3 years after initiating androgen receptor agonist therapy as part of his gender identity transition. After mastectomy, adjuvant endocrine therapy was initiated, consisting of a combination of an aromatase inhibitor and a gonadotropin-releasing hormone agonist, along with a cross-sex hormone. Conclusion: Estradiol levels were significantly reduced, and male-typical levels of sex hormones were attained. |
| doi_str_mv | 10.1159/000536212 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38327829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A798455238</galeid><doaj_id>oai_doaj_org_article_98b7cfff5b0b4a17899dceb823305312</doaj_id><sourcerecordid>A798455238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-10a1b8d8e096f4ae6bac8f0c20fac60e1545b776c9a2ba31995976c6e26fb2e63</originalsourceid><addsrcrecordid>eNptkk1v1DAQQCMEoqVw4I5QpJ44pPgjduwTWlYtVCoqQsvZmjjjrZfE3jrZiv57vKSsWgn5YHvm-ckeT1G8peSMUqE_EkIEl4yyZ8UxlZJVUjTi-aP1UfFqHDeESC2keFkcccVZo5g-LuwyDtsef_vJ41j6UC66ze4OwlSehy7a5AOWqxtMsL0vXUzl54QwTuUSgsW05y9wgB6rKVbf8lyuEoRxjaHL2e-QpWEaXxcvHPQjvnmYT4qfF-er5dfq6vrL5XJxVVlB-VRRArRVnUKipasBZQtWOWIZcWAlQSpq0TaNtBpYC5xqLXTeSWTStQwlPykuZ28XYWO2yQ-Q7k0Eb_4GYlobSJO3PRqt2sY650RL2hpoo7TuLLaKcZ5LSVl2fZpd2107YM6FKUH_RPo0E_yNWcc7Q4mqdVOrbDh9MKR4u8NxMpu4SyEXwHDSEEE0FU2mzmZqnatnfHAx22weHQ7exoDO5_ii0aoWgvG99sN8wKY4jgnd4U6UmH03mEM3ZPb940ccyH_fn4F3M_AL0hrTATicP_1vevnjeibMtnP8Dz2VxG0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070509157</pqid></control><display><type>article</type><title>Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>Sato, Shoko ; Imada, Sae ; Hayami, Ryosuke ; Arai, Kazumori ; Kosugi, Rieko ; Tsuneizumi, Michiko ; Matsunuma, Ryoichi</creator><creatorcontrib>Sato, Shoko ; Imada, Sae ; Hayami, Ryosuke ; Arai, Kazumori ; Kosugi, Rieko ; Tsuneizumi, Michiko ; Matsunuma, Ryoichi</creatorcontrib><description>Abstract
Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore, the considerations for adjuvant endocrine therapy in this population are highly intricate and warrant thorough discussion. Case Presentation: We describe the case of a 44-year-old FtM transgender diagnosed with breast cancer 3 years after initiating androgen receptor agonist therapy as part of his gender identity transition. After mastectomy, adjuvant endocrine therapy was initiated, consisting of a combination of an aromatase inhibitor and a gonadotropin-releasing hormone agonist, along with a cross-sex hormone. Conclusion: Estradiol levels were significantly reduced, and male-typical levels of sex hormones were attained.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000536212</identifier><identifier>PMID: 38327829</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adjuvant treatment ; Androgens ; Breast cancer ; Cancer ; Cancer therapies ; Case Report ; Case reports ; Endocrine therapy ; Estradiol ; Estrogens ; female-to-male transgender ; Females ; Gender dysphoria ; Gender identity ; Health aspects ; Hormones ; Lymphatic system ; Magnetic resonance imaging ; Mammography ; Patients ; Pituitary hormones ; Testosterone ; Transgender people ; Transgender persons ; Womens health</subject><ispartof>Case Reports in Oncology, 2024-01, Vol.17 (1), p.208-216</ispartof><rights>2024 The Author(s). Published by S. Karger AG, Basel</rights><rights>2024 The Author(s). Published by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2024 S. Karger AG</rights><rights>2024 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><rights>2024 The Author(s). Published by S. Karger AG, Basel 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c513t-10a1b8d8e096f4ae6bac8f0c20fac60e1545b776c9a2ba31995976c6e26fb2e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849748/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849748/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38327829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sato, Shoko</creatorcontrib><creatorcontrib>Imada, Sae</creatorcontrib><creatorcontrib>Hayami, Ryosuke</creatorcontrib><creatorcontrib>Arai, Kazumori</creatorcontrib><creatorcontrib>Kosugi, Rieko</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Matsunuma, Ryoichi</creatorcontrib><title>Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients</title><title>Case Reports in Oncology</title><addtitle>Case Rep Oncol</addtitle><description>Abstract
Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore, the considerations for adjuvant endocrine therapy in this population are highly intricate and warrant thorough discussion. Case Presentation: We describe the case of a 44-year-old FtM transgender diagnosed with breast cancer 3 years after initiating androgen receptor agonist therapy as part of his gender identity transition. After mastectomy, adjuvant endocrine therapy was initiated, consisting of a combination of an aromatase inhibitor and a gonadotropin-releasing hormone agonist, along with a cross-sex hormone. Conclusion: Estradiol levels were significantly reduced, and male-typical levels of sex hormones were attained.</description><subject>Adjuvant treatment</subject><subject>Androgens</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Endocrine therapy</subject><subject>Estradiol</subject><subject>Estrogens</subject><subject>female-to-male transgender</subject><subject>Females</subject><subject>Gender dysphoria</subject><subject>Gender identity</subject><subject>Health aspects</subject><subject>Hormones</subject><subject>Lymphatic system</subject><subject>Magnetic resonance imaging</subject><subject>Mammography</subject><subject>Patients</subject><subject>Pituitary hormones</subject><subject>Testosterone</subject><subject>Transgender people</subject><subject>Transgender persons</subject><subject>Womens health</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQQCMEoqVw4I5QpJ44pPgjduwTWlYtVCoqQsvZmjjjrZfE3jrZiv57vKSsWgn5YHvm-ckeT1G8peSMUqE_EkIEl4yyZ8UxlZJVUjTi-aP1UfFqHDeESC2keFkcccVZo5g-LuwyDtsef_vJ41j6UC66ze4OwlSehy7a5AOWqxtMsL0vXUzl54QwTuUSgsW05y9wgB6rKVbf8lyuEoRxjaHL2e-QpWEaXxcvHPQjvnmYT4qfF-er5dfq6vrL5XJxVVlB-VRRArRVnUKipasBZQtWOWIZcWAlQSpq0TaNtBpYC5xqLXTeSWTStQwlPykuZ28XYWO2yQ-Q7k0Eb_4GYlobSJO3PRqt2sY650RL2hpoo7TuLLaKcZ5LSVl2fZpd2107YM6FKUH_RPo0E_yNWcc7Q4mqdVOrbDh9MKR4u8NxMpu4SyEXwHDSEEE0FU2mzmZqnatnfHAx22weHQ7exoDO5_ii0aoWgvG99sN8wKY4jgnd4U6UmH03mEM3ZPb940ccyH_fn4F3M_AL0hrTATicP_1vevnjeibMtnP8Dz2VxG0</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Sato, Shoko</creator><creator>Imada, Sae</creator><creator>Hayami, Ryosuke</creator><creator>Arai, Kazumori</creator><creator>Kosugi, Rieko</creator><creator>Tsuneizumi, Michiko</creator><creator>Matsunuma, Ryoichi</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240101</creationdate><title>Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients</title><author>Sato, Shoko ; Imada, Sae ; Hayami, Ryosuke ; Arai, Kazumori ; Kosugi, Rieko ; Tsuneizumi, Michiko ; Matsunuma, Ryoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-10a1b8d8e096f4ae6bac8f0c20fac60e1545b776c9a2ba31995976c6e26fb2e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adjuvant treatment</topic><topic>Androgens</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Endocrine therapy</topic><topic>Estradiol</topic><topic>Estrogens</topic><topic>female-to-male transgender</topic><topic>Females</topic><topic>Gender dysphoria</topic><topic>Gender identity</topic><topic>Health aspects</topic><topic>Hormones</topic><topic>Lymphatic system</topic><topic>Magnetic resonance imaging</topic><topic>Mammography</topic><topic>Patients</topic><topic>Pituitary hormones</topic><topic>Testosterone</topic><topic>Transgender people</topic><topic>Transgender persons</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sato, Shoko</creatorcontrib><creatorcontrib>Imada, Sae</creatorcontrib><creatorcontrib>Hayami, Ryosuke</creatorcontrib><creatorcontrib>Arai, Kazumori</creatorcontrib><creatorcontrib>Kosugi, Rieko</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Matsunuma, Ryoichi</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sato, Shoko</au><au>Imada, Sae</au><au>Hayami, Ryosuke</au><au>Arai, Kazumori</au><au>Kosugi, Rieko</au><au>Tsuneizumi, Michiko</au><au>Matsunuma, Ryoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients</atitle><jtitle>Case Reports in Oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>17</volume><issue>1</issue><spage>208</spage><epage>216</epage><pages>208-216</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>Abstract
Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore, the considerations for adjuvant endocrine therapy in this population are highly intricate and warrant thorough discussion. Case Presentation: We describe the case of a 44-year-old FtM transgender diagnosed with breast cancer 3 years after initiating androgen receptor agonist therapy as part of his gender identity transition. After mastectomy, adjuvant endocrine therapy was initiated, consisting of a combination of an aromatase inhibitor and a gonadotropin-releasing hormone agonist, along with a cross-sex hormone. Conclusion: Estradiol levels were significantly reduced, and male-typical levels of sex hormones were attained.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>38327829</pmid><doi>10.1159/000536212</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6575 |
| ispartof | Case Reports in Oncology, 2024-01, Vol.17 (1), p.208-216 |
| issn | 1662-6575 1662-6575 |
| language | eng |
| recordid | cdi_pubmed_primary_38327829 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Karger Open Access |
| subjects | Adjuvant treatment Androgens Breast cancer Cancer Cancer therapies Case Report Case reports Endocrine therapy Estradiol Estrogens female-to-male transgender Females Gender dysphoria Gender identity Health aspects Hormones Lymphatic system Magnetic resonance imaging Mammography Patients Pituitary hormones Testosterone Transgender people Transgender persons Womens health |
| title | Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A00%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complexities%20in%20Adjuvant%20Endocrine%20Therapy%20for%20Breast%20Cancer%20in%20Female-to-Male%20Transgender%20Patients&rft.jtitle=Case%20Reports%20in%20Oncology&rft.au=Sato,%20Shoko&rft.date=2024-01-01&rft.volume=17&rft.issue=1&rft.spage=208&rft.epage=216&rft.pages=208-216&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000536212&rft_dat=%3Cgale_pubme%3EA798455238%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070509157&rft_id=info:pmid/38327829&rft_galeid=A798455238&rft_doaj_id=oai_doaj_org_article_98b7cfff5b0b4a17899dceb823305312&rfr_iscdi=true |